Literature DB >> 23326180

THE POLITICS OF RISK AND EU GOVERNANCE OF HUMAN MATERIAL.

Anne-Maree Farrel1.   

Abstract

This paper examines the politics of EU risk governance in relation to human material. It is argued that the political context has informed the way in which risks in relation to various types of human material have come to be defined as policy problems at EU level. In turn, this has influenced the design and/or persistence of institutional arrangements to manage such problems. It is further argued that this political context has resulted in a significant level of disconnection in risk governance in the area. This has happened in two ways. First, there has been a growing level of disconnection between institutional and stakeholder demands for a more expansive approach to risk governance in the area and the narrowly-circumscribed competence under Article 152(4)(a) EC, which permits the adoption of risk regulation regimes that set minimum standards of quality and safety in relation to blood, tissue/cells and organs. Second, it has led to the development of institutional arrangements that promote a bifurcated approach to risk governance, specifically in relation to blood and tissues/cells. Although a hybrid of traditional and new governance mechanisms have been employed to address this problem of disconnection, this has nevertheless added a further layer to already complex institutional arrangements for risk governance in the area. It is suggested that a more integrated approach to EU risk governance in relation to human material is needed. Implementing such an approach would contribute to greater clarity, transparency and accountability in decision-making processes, and this could enhance public trust in what is a politically-sensitive area of governance at EU level.

Entities:  

Year:  2009        PMID: 23326180      PMCID: PMC3544943          DOI: 10.1177/1023263X0901600103

Source DB:  PubMed          Journal:  Maastrich J Eur Comp Law        ISSN: 1023-263X


  14 in total

1.  The European Group on Ethics in Science and New Technologies to the European Commission. Adoption of an opinion on ethical aspects of human stem cell research and use.

Authors: 
Journal:  Rev Derecho Genoma Hum       Date:  2001 Jul-Dec

2.  Factors influencing the adaptation of the Spanish Model of organ donation.

Authors:  Rafael Matesanz
Journal:  Transpl Int       Date:  2003-07-03       Impact factor: 3.782

3.  Gift or good? A contemporary examination of the voluntary and commercial aspects of blood donation.

Authors:  R W Beal; W G van Aken
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

4.  Creating public alienation: expert cultures of risk and ethics on GMOs.

Authors:  B Wynne
Journal:  Sci Cult (Lond)       Date:  2001-12

5.  Is the gift still good? Examining the politics and regulation of blood safety in the European Union.

Authors:  Anne-Maree Farrell
Journal:  Med Law Rev       Date:  2006-05-03       Impact factor: 1.267

Review 6.  The European Union Blood Safety Directive and its implications for blood services.

Authors:  E Angela E Robinson
Journal:  Vox Sang       Date:  2007-08       Impact factor: 2.144

7.  The gift of blood in Europe: an ethical defence of EC directive 89/381.

Authors:  J Keown
Journal:  J Med Ethics       Date:  1997-04       Impact factor: 2.903

8.  Donated blood--gift or commodity? Some economic and ethical considerations on voluntary vs commercial donation of blood.

Authors:  H von Schubert
Journal:  Soc Sci Med       Date:  1994-07       Impact factor: 4.634

9.  An ethical framework for stem cell research in the European Union.

Authors:  John Harris; Lisa Bortolotti; Louise Irving
Journal:  Health Care Anal       Date:  2005-09

10.  Recombinant proteins in therapeutics: haemophilia treatment as an example.

Authors:  Antonio Liras
Journal:  Int Arch Med       Date:  2008-04-28
View more
  1 in total

1.  Revaluing donor and recipient bodies in the globalised blood economy: transitions in public policy on blood safety in the United Kingdom.

Authors:  Helen Busby; Julie Kent; Anne-Maree Farrell
Journal:  Health (London)       Date:  2013-03-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.